{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:23:02Z","timestamp":1791332582935,"version":"4.3.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.4158\/ep09154.ra","type":"journal-article","created":{"date-parts":[[2010,1,14]],"date-time":"2010-01-14T21:36:13Z","timestamp":1263504973000},"page":"310-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Clinical Classification and Treatment of Congenital and Acquired Lipodystrophy"],"prefix":"10.1016","volume":"16","author":[{"given":"Jean L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif A.","family":"Oral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP09154.RA_bb0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/MOL.0b013e32832d3bb1","article-title":"Clinical management of HIV-associated lipodystrophy","volume":"20","author":"Pirmohamed","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.4158\/EP09154.RA_bb0015","first-page":"126","article-title":"Disorders of body fat distribution in HIV-1-infected patients","volume":"11","author":"Moreno","year":"2009","journal-title":"AIDS Rev"},{"key":"10.4158\/EP09154.RA_bb0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11904-008-0010-8","article-title":"Pathogenesis and management of lipoatrophy","volume":"5","author":"Tungsiripat","year":"2008","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.4158\/EP09154.RA_bb0025","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1210\/jc.2002-021704","article-title":"Clinical review 159: human immunodeficiency virus\/highly active antiretroviral therapy-associated metabolic syndrome; clinical presentation, pathophysiology, and therapeutic strategies","volume":"88","author":"Leow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0030","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1043-2760(00)00309-X","article-title":"Lipoatrophy revisited","volume":"11","author":"Reitman","year":"2000","journal-title":"Trends Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0035","first-page":"436","article-title":"Metabolic consequences of lipodystrophy in mouse models","volume":"9","author":"Reue","year":"2006","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.4158\/EP09154.RA_bb0040","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1210\/jcem.84.9.6103","article-title":"A gene for congenital generalized lipodystrophy maps to human chromosome 9q34","volume":"84","author":"Garg","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1651-2227.1996.tb14262.x","article-title":"Generalized lipodystrophy, congenital and acquired (lipoatrophy)","volume":"413","author":"Seip","year":"1996","journal-title":"Acta Paediatr Suppl"},{"key":"10.4158\/EP09154.RA_bb0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1651-2227.1996.tb14265.x","article-title":"Radiological features in generalized lipodystrophy","volume":"413","author":"Westvik","year":"1996","journal-title":"Acta Paediatr Suppl"},{"key":"10.4158\/EP09154.RA_bb0055","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00241817","article-title":"The skeleton in congenital, generalized lipodystrophy: evaluation using whole-body radiographic surveys, magnetic resonance imaging and technetium-99m bone scintigraphy","volume":"21","author":"Fleckenstein","year":"1992","journal-title":"Skeletal Radiol"},{"key":"10.4158\/EP09154.RA_bb0060","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1210\/jc.2003-030855","article-title":"Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy","volume":"88","author":"Agarwal","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0065","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1034\/j.1399-0004.2002.610407.x","article-title":"Cardiomyopathy in congenital complete lipodystrophy","volume":"61","author":"Bhayana","year":"2002","journal-title":"Clin Genet"},{"key":"10.4158\/EP09154.RA_bb0070","first-page":"111","article-title":"Lipodystrophy of the extremities: a dominantly inherited syndrome associated with lipatrophic diabetes","volume":"29","author":"K\u00f6bberling","year":"1975","journal-title":"Humangenetik"},{"key":"10.4158\/EP09154.RA_bb0075","first-page":"33","article-title":"Familial lipoatrophic diabetes with dominant transmission: a new syndrome","volume":"43","author":"Dunnigan","year":"1974","journal-title":"Q J Med"},{"key":"10.4158\/EP09154.RA_bb0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/jmg.23.2.120","article-title":"Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state","volume":"23","author":"K\u00f6bberling","year":"1986","journal-title":"J Med Genet"},{"key":"10.4158\/EP09154.RA_bb0085","first-page":"170","article-title":"Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety)","volume":"84","author":"Garg","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0090","first-page":"1776","article-title":"Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety)","volume":"85","author":"Garg","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0095","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2005.00234.x","article-title":"Hepatic steatosis in Dunnigan-type familial partial lipodystrophy","volume":"100","author":"L\u00fcdtke","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.4158\/EP09154.RA_bb0100","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.2337\/diabetes.49.11.1958","article-title":"Lamin A\/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy","volume":"49","author":"Vigouroux","year":"2000","journal-title":"Diabetes"},{"key":"10.4158\/EP09154.RA_bb0105","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2337\/diacare.26.5.1350","article-title":"Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety","volume":"26","author":"Haque","year":"2003","journal-title":"Diabetes Care"},{"key":"10.4158\/EP09154.RA_bb0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.4158\/EP09154.RA_bb0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/jc.2008-1703","article-title":"Complement abnormalities in acquired lipodystrophy revisited","volume":"94","author":"Savage","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0120","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1365-4632.2006.02888.x","article-title":"Peripheral T-cell lymphoma presenting as lipoatrophy and nodules","volume":"45","author":"Yiannias","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.4158\/EP09154.RA_bb0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.4158\/EP09154.RA_bb0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MD.0b013e31816bc604","article-title":"Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity","volume":"87","author":"Bingham","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.4158\/EP09154.RA_bb0135","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1310\/hct0905-314","article-title":"A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy","volume":"9","author":"Walmsley","year":"2008","journal-title":"HIV Clin Trials"},{"key":"10.4158\/EP09154.RA_bb0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-008-0010-6","article-title":"HIV therapy, metabolic syndrome, and cardiovascular risk","volume":"10","author":"Pao","year":"2008","journal-title":"Curr Atheroscler Rep"},{"key":"10.4158\/EP09154.RA_bb0145","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1086\/375886","article-title":"Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome","volume":"37","author":"Grunfeld","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.4158\/EP09154.RA_bb0150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00126334-200312150-00003","article-title":"Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study","volume":"34","author":"Tien","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.4158\/EP09154.RA_bb0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00001432-200402000-00005","article-title":"What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection","volume":"17","author":"Tien","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"10.4158\/EP09154.RA_bb0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coph.2008.11.010","article-title":"Lysophosphatidic acid (LPA) and its receptors","volume":"9","author":"Noguchi","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.4158\/EP09154.RA_bb0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cmet.2009.01.002","article-title":"Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy","volume":"9","author":"Cortes","year":"2009","journal-title":"Cell Metab"},{"key":"10.4158\/EP09154.RA_bb0170","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ng585","article-title":"Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13","volume":"28","author":"Magr\u00e9","year":"2001","journal-title":"Nat Genet"},{"key":"10.4158\/EP09154.RA_bb0175","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.febslet.2006.03.040","article-title":"Membrane topology of the human seipin protein","volume":"580","author":"Lundin","year":"2006","journal-title":"FEBS Lett"},{"key":"10.4158\/EP09154.RA_bb0180","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.biochi.2009.01.011","article-title":"Seipin deficiency alters fatty acid delta9 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy","volume":"91","author":"Boutet","year":"2009","journal-title":"Biochimie"},{"key":"10.4158\/EP09154.RA_bb0185","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/brain\/awn216","article-title":"Seipinopathy: a novel endoplasmic reticulum stress-associated disease","volume":"132","author":"Ito","year":"2009","journal-title":"Brain"},{"key":"10.4158\/EP09154.RA_bb0190","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/jnnp.2008.165977","article-title":"Complementary mutations in seipin gene in a patient with Berardinelli-Seip congenital lipodystrophy and dystonia: phenotype variability suggests multiple roles of seipin gene","volume":"80","author":"Wu","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.4158\/EP09154.RA_bb0195","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1210\/jc.2003-030415","article-title":"Mutations in the seipin and AGPAT2 genes clustering in consanguineous families with Berardinelli-Seip congenital lipodystrophy from two separate geographical regions of Brazil","volume":"89","author":"Gomes","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0200","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s10545-005-0038-5","article-title":"Phenotypic heterogeneity in biochemical parameters correlates with mutations in AGPAT2 or seipin genes among Berardinelli-Seip congenital lipodystrophy patients","volume":"28","author":"Gomes","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.4158\/EP09154.RA_bb0205","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1210\/jc.2003-031211","article-title":"Gene and phenotype analysis of congenital generalized lipodystrophy in Japanese: a novel homozygous nonsense mutation in seipin gene","volume":"89","author":"Ebihara","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0210","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1210\/jc.2007-1328","article-title":"Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy","volume":"93","author":"Kim","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0215","doi-asserted-by":"crossref","first-page":"8635","DOI":"10.1074\/jbc.M110970200","article-title":"Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities","volume":"277","author":"Razani","year":"2002","journal-title":"J Biol Chem"},{"key":"10.4158\/EP09154.RA_bb0220","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1172\/JCI38660","article-title":"Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy","volume":"119","author":"Hayashi","year":"2009","journal-title":"J Clin Invest"},{"key":"10.4158\/EP09154.RA_bb0225","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/ajmg.a.32457","article-title":"Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability","volume":"146A","author":"Simha","year":"2008","journal-title":"Am J Med Genet A"},{"key":"10.4158\/EP09154.RA_bb0230","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0962-8924(99)01708-0","article-title":"The nuclear envelope, muscular dystrophy and gene expression","volume":"10","author":"Wilson","year":"2000","journal-title":"Trends Cell Biol"},{"key":"10.4158\/EP09154.RA_bb0235","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1006\/bbrc.1999.2023","article-title":"Direct interaction between emerin and lamin A","volume":"267","author":"Clements","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.4158\/EP09154.RA_bb0240","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/nrg1906","article-title":"Human laminopathies: nuclei gone genetically awry","volume":"7","author":"Capell","year":"2006","journal-title":"Nat Rev Genet"},{"key":"10.4158\/EP09154.RA_bb0245","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1194\/jlr.M800491-JLR200","article-title":"The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation","volume":"50","author":"Wojtanik","year":"2009","journal-title":"J Lipid Res"},{"key":"10.4158\/EP09154.RA_bb0250","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/hmg\/ddg213","article-title":"Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia","volume":"12","author":"Agarwal","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.4158\/EP09154.RA_bb0255","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1210\/jc.2007-0654","article-title":"New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome","volume":"92","author":"Decaudain","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0260","doi-asserted-by":"crossref","first-page":"39741","DOI":"10.1074\/jbc.R600033200","article-title":"Prelamin A farnesylation and progeroid syndromes","volume":"281","author":"Young","year":"2006","journal-title":"J Biol Chem"},{"key":"10.4158\/EP09154.RA_bb0265","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1124875","article-title":"A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria","volume":"311","author":"Fong","year":"2006","journal-title":"Science"},{"key":"10.4158\/EP09154.RA_bb0270","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/47254","article-title":"Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension","volume":"402","author":"Barroso","year":"1999","journal-title":"Nature"},{"key":"10.4158\/EP09154.RA_bb0275","first-page":"408","article-title":"A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy","volume":"87","author":"Agarwal","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0280","first-page":"51","article-title":"Peroxisome proliferator-activated receptor-gamma and insulin action: insights from human genetics","volume":"60","author":"Chatterjee","year":"2003","journal-title":"Horm Res"},{"key":"10.4158\/EP09154.RA_bb0285","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.tem.2009.04.005","article-title":"Functional implications of genetic variation in human PPARgamma","volume":"20","author":"Jeninga","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0290","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2337\/db06-0921","article-title":"Analysis of genetic variation in Akt2\/PKB-beta in severe insulin resistance, lipodystrophy, type 2 diabetes, and related metabolic phenotypes","volume":"56","author":"Tan","year":"2007","journal-title":"Diabetes"},{"key":"10.4158\/EP09154.RA_bb0295","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.2337\/db08-0422","article-title":"Evaluating the role of LPIN1 variation in insulin resistance, body weight, and human lipodystrophy in U.K. populations","volume":"57","author":"Fawcett","year":"2008","journal-title":"Diabetes"},{"key":"10.4158\/EP09154.RA_bb0300","doi-asserted-by":"crossref","first-page":"33623","DOI":"10.1074\/jbc.M109.049395","article-title":"Lipase maturation factor LMF1, membrane topology and interaction with lipase proteins in the endoplasmic reticulum","volume":"284","author":"Doolittle","year":"2009","journal-title":"J Biol Chem"},{"key":"10.4158\/EP09154.RA_bb0305","first-page":"3431","article-title":"Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy","volume":"85","author":"Hegele","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0310","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-511X-7-3","article-title":"Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia","volume":"7","author":"Cao","year":"2008","journal-title":"Lipids Health Dis"},{"key":"10.4158\/EP09154.RA_bb0315","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest"},{"key":"10.4158\/EP09154.RA_bb0320","first-page":"315","article-title":"Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis","volume":"119","author":"Semple","year":"2009","journal-title":"J Clin Invest"},{"key":"10.4158\/EP09154.RA_bb0325","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1161\/01.CIR.103.18.2225","article-title":"Premature atherosclerosis associated with monogenic insulin resistance","volume":"103","author":"Hegele","year":"2001","journal-title":"Circulation"},{"key":"10.4158\/EP09154.RA_bb0330","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2337\/diab.44.8.863","article-title":"Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications","volume":"44","author":"Unger","year":"1995","journal-title":"Diabetes"},{"key":"10.4158\/EP09154.RA_bb0335","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1210\/jcem.84.12.6237","article-title":"Genetically defined forms of diabetes in children","volume":"84","author":"Taylor","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0340","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1210\/jcem.87.7.8591","article-title":"Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy","volume":"87","author":"Oral","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0345","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.med.57.022605.114424","article-title":"Genetic basis of lipodystrophies and management of metabolic complications","volume":"57","author":"Agarwal","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.4158\/EP09154.RA_bb0350","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/jc.2003-032140","article-title":"Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy","volume":"89","author":"Javor","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0355","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ndt\/12.1.226","article-title":"The patient with glomerulonephritis and lipodystrophy","volume":"12","author":"Meyrier","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.4158\/EP09154.RA_bb0360","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00007890-197809000-00009","article-title":"Renal transplantation in a patient with lipoatrophic diabetes: a case report","volume":"26","author":"Casali","year":"1978","journal-title":"Transplantation"},{"key":"10.4158\/EP09154.RA_bb0365","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4158\/EP09154.RA_bb0370","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4158\/EP09155.RA","article-title":"Rationale for leptin-replacement therapy for severe lipodystrophy","volume":"16","author":"Oral","year":"2010","journal-title":"Endocr Pract"},{"key":"10.4158\/EP09154.RA_bb0375","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.clinbiochem.2009.03.006","article-title":"Serum retinol binding protein 4 in patients with familial partial lipodystrophy","volume":"42","author":"Godoy-Matos","year":"2009","journal-title":"Clin Biochem"},{"key":"10.4158\/EP09154.RA_bb0380","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0385","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s00125-005-0038-x","article-title":"Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation lamin A\/C","volume":"48","author":"Wong","year":"2005","journal-title":"Diabetologia"},{"key":"10.4158\/EP09154.RA_bb0390","doi-asserted-by":"crossref","first-page":"307","DOI":"10.7326\/0003-4819-149-5-200809020-00005","article-title":"Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women","volume":"149","author":"Heidemann","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP09154.RA_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-007-0001-y","article-title":"Leptin and adiponectin: their role in diabetes","volume":"7","author":"Brennan","year":"2007","journal-title":"Curr Diab Rep"},{"key":"10.4158\/EP09154.RA_bb0400","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1210\/jc.2002-020795","article-title":"Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy","volume":"88","author":"Addy","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0405","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP09154.RA_bb0410","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1464-5491.2005.01757.x","article-title":"Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone","volume":"22","author":"L\u00fcdtke","year":"2005","journal-title":"Diabet Med"},{"key":"10.4158\/EP09154.RA_bb0415","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4158\/EP.13.6.656","article-title":"Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome","volume":"13","author":"Sleilati","year":"2007","journal-title":"Endocr Pract"},{"key":"10.4158\/EP09154.RA_bb0420","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.diabet.2007.04.005","article-title":"Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report","volume":"33","author":"Moreau","year":"2007","journal-title":"Diabetes Metab"},{"key":"10.4158\/EP09154.RA_bb0425","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.metabol.2009.04.043","article-title":"Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy","volume":"58","author":"Iwanishi","year":"2009","journal-title":"Metabolism"},{"key":"10.4158\/EP09154.RA_bb0430","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1464-5491.2003.01034.x","article-title":"Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene","volume":"20","author":"Owen","year":"2003","journal-title":"Diabet Med"},{"key":"10.4158\/EP09154.RA_bb0435","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1210\/en.2003-1271","article-title":"Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma","volume":"145","author":"Agostini","year":"2004","journal-title":"Endocrinology"},{"key":"10.4158\/EP09154.RA_bb0440","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1463-1326.2008.00978.x","article-title":"Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety","volume":"10","author":"Simha","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP09154.RA_bb0445","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.4158\/EP09154.RA_bb0450","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1055\/s-0029-1202779","article-title":"The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in HIV-positive patients on highly-active antiretroviral therapy (HAART)","volume":"41","author":"Schindler","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP09154.RA_bb0455","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial","volume":"140","author":"Hadigan","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP09154.RA_bb0460","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ghir.2005.05.002","article-title":"Rh\/IGF-I\/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose","volume":"15","author":"Clemmons","year":"2005","journal-title":"Growth Horm IGF Res"},{"key":"10.4158\/EP09154.RA_bb0465","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000085762","article-title":"Insulin resistance and type 2 diabetes mellitus: is there a therapeutic role for IGF-1?","volume":"9","author":"Moses","year":"2005","journal-title":"Endocr Dev"},{"key":"10.4158\/EP09154.RA_bb0470","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0026-0495(00)90418-9","article-title":"Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies","volume":"49","author":"Goldfine","year":"2000","journal-title":"Metabolism"},{"key":"10.4158\/EP09154.RA_bb0475","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"key":"10.4158\/EP09154.RA_bb0480","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1530\/EJE-08-0272","article-title":"Monogenic polycystic ovary syndrome due to a mutation in the lamin A\/C gene is sensitive to thiazolidinediones but not to metformin","volume":"159","author":"Gambineri","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP09154.RA_bb0485","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1210\/jcem.87.1.8176","article-title":"Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy","volume":"87","author":"Bolan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09154.RA_bb0490","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0b013e32832d4a33","article-title":"Inherited lipodystrophies and hypertriglyceridemia","volume":"20","author":"Simha","year":"2009","journal-title":"Curr Opin Lipidol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20419640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20419640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/E2410H1V45384P11.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:52:02Z","timestamp":1761515522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20419640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1530891X20419640"],"URL":"https:\/\/doi.org\/10.4158\/ep09154.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Classification and Treatment of Congenital and Acquired Lipodystrophy","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP09154.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}